NDAORALCAPSULEPriority Review
Approved
Nov 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
ZARONTIN (ethosuximide) by Pfizer is clinical pharmacology ethosuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. Approved for epilepsy. First approved in 1960.
Drug data last refreshed 6h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZARONTIN (ethosuximide) is an oral anti-epileptic agent approved in 1960 that suppresses the characteristic 3 Hz spike-and-wave activity associated with absence seizures by depressing motor cortex activity and elevating seizure threshold. It is indicated specifically for absence (petit mal) epilepsy and remains a foundational therapy in absence seizure management.
$0.217MPart D
LOE ApproachingDeclining
As an aging product approaching loss of exclusivity with modest Part D utilization (335 claims), the brand team is likely small and focused on cost-containment and specialist relationships rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Ethosuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. The frequency of epileptiform attacks is reduced, apparently by depression of the motor cortex and…
Pharmacologic Class:
Anti-epileptic Agent
Indications (1)
Career Relevance
Working on ZARONTIN offers limited career growth potential given its mature, declining market position and approaching LOE; opportunities are primarily in payer management, cost optimization, and sales force oversight rather than innovation or market expansion. This role is best suited for professionals seeking stable, specialized expertise in a niche indication or transition to generic/biosimilar portfolio management.
Worked on ZARONTIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.